Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,308 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Biological Markers Clear all
Withdrawn Phase 1Phase 2 Interventional

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

NCT02736123
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes

NCT04164966
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting No phase listed Observational

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

NCT05781113
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Celestra Health Systems
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting Phase 2 Interventional

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 2 Interventional

Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)

NCT00002079
View directory record Official record
Conditions
HIV Infections
Interventions
Butyldeoxynojirimycin, Zidovudine
Drug
Lead sponsor
G D Searle
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Tarzana, California • Miami Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 13, 2026, 9:52 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing IVF

NCT02591186
View directory record Official record
Conditions
Infertility
Interventions
Acupuncture
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 42 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting No phase listed Observational

Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy

NCT05016908
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years and older
Enrollment
100 participants
Timeline
2019 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01258855
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
21
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1 Interventional Results available

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1 Interventional

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

NCT05195918
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Combination Product
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Not listed No phase listed Observational

Risk Stratification of COVID-19 Using Urine Biomarkers

NCT04681040
View directory record Official record
Conditions
Covid19, Urine, Biomarker, Acute Respiratory Failure With Hypoxia
Interventions
Not listed
Lead sponsor
National Center for Global Health and Medicine, Japan
Government
Eligibility
20 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Nov 13, 2026, 9:52 AM EST
Withdrawn Not applicable Interventional

Precision Brain Mapping to Predict and Track Response to Exposure and Response Prevention Therapy in Youth With Obsessive-Compulsive Disorder

NCT07570108
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Exposure and Response Prevention Therapy, Clinical Assessments, Research MRI Sessions
Behavioral · Other · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
10 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

NCT00899548
View directory record Official record
Conditions
Breast Cancer
Interventions
DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
4
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Nov 13, 2026, 9:52 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Low-field MRI for Breast Cancer Screening

NCT05486520
View directory record Official record
Conditions
Breast Benign, Malignant Neoplasm of Breast, Breast Malignant Tumor
Interventions
Magnetic Resonance Imaging (MRI)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting No phase listed Observational

Precise and Objective Identification of Bertolotti Syndrome Using Novel Kinematic Biomarkers

NCT06225583
View directory record Official record
Conditions
Bertolotti's Syndrome, Lower Back Pain
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed No phase listed Observational

Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer

NCT00579462
View directory record Official record
Conditions
Lung Cancer
Interventions
Blood and Tissue studies
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Nov 13, 2026, 9:52 AM EST
Completed No phase listed Observational

Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)

NCT01909362
View directory record Official record
Conditions
Colorectal Neoplasms, Advanced Metastatic Colorectal Cancer
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Incl Greenville, SC and Tyler, TX, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

NCT05425446
View directory record Official record
Conditions
Celiac Disease
Interventions
DONQ52, Placebo
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Anniston, Alabama • Denver, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Nov 13, 2026, 9:52 AM EST
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Ankle-Brachial Index Changes Post Exercise and Its Effects on Patient-Centered Outcomes and Gait

NCT07637396
View directory record Official record
Conditions
Peripheral Arterial Disease(PAD)
Interventions
Not listed
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy

NCT02839460
View directory record Official record
Conditions
Sarcopenia
Interventions
Outpatient Muscle Biopsy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Nov 13, 2026, 9:52 AM EST
Completed No phase listed Observational

Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation

NCT02134379
View directory record Official record
Conditions
Heart Failure; With Decompensation
Interventions
Medtronic ICDs, CRT-Ds, and CRT-Ps
Device
Lead sponsor
Charles Porter, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Nov 13, 2026, 9:52 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

NCT02477462
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Clinic visit, Baseline visit
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting Phase 1 Interventional

A Study of LY3439539 in Participants With Alzheimer's Disease

NCT07598370
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3439539
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting Phase 2 Interventional

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

NCT06940427
View directory record Official record
Conditions
Fibrosis Lung
Interventions
FAPI tracer, PET/MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 13, 2026, 9:52 AM EST